宏源药业股票讨论区

Despite a drop in earnings, Hubei Hongyuan Pharmaceutical's high P/E ratio suggests investors may be overly optimistic. Continued earnings trends could pose a risk to shareholders and potential investors.

Investors overlook the company's dismal growth, banking on business recovery. But enduring earning downturns may hurt the share price, making the high P/E ratio untenable.